Back to top
more

Envista (NVST)

(Real Time Quote from BATS)

$16.36 USD

16.36
1,112,796

-0.14 (-0.85%)

Updated Aug 9, 2024 11:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

New Strong Buy Stocks for May 7th

by Zacks Equity Research

CBT, OMI, ARCB, BWFG, and NVST have been added to the Zacks Rank #1 (Strong Buy) List on May 7, 2021.

Envista (NVST) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Envista (NVST) delivered earnings and revenue surprises of 74.19% and 11.35%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Why Investors Need to Take Advantage of the Zacks ESP Screener

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Envista (NVST) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Envista (NVST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Envista (NVST) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Envista (NVST) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Here's Why You Should Hold on to Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL) owing to its progress with its three-legged strategic, which is driving growth and an impressive 2025 roadmap.

Cardiovascular Systems (CSII) Inks Deal to Enhance Patient Care

by Zacks Equity Research

Cardiovascular Systems' (CSII) investment in CarePICS will advance patient access to the suitable treatment at the right time, thereby leading to improved care and reduced amputations.

Envista (NVST) Soars 6.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Envista (NVST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

CVS Health (CVS) Extends COVID-19 Antibody Testing Nationwide

by Zacks Equity Research

CVS Health's (CVS) antibody test detects for previous infection to COVID-19 and provides results within 15 minutes.

NuVasive's (NUVA) Simply Cervical Artificial Disc Gets FDA Nod

by Zacks Equity Research

NuVasive's (NUVA) Simplify Disc demonstrated an overall clinical success rate nearly 10% higher than the anterior cervical discectomy and fusion.

Medtronic (MDT) Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

Medtronic's (MDT) ventilator sales are robust and prospects of the Diabetes arm remain strong amid the pandemic.

Abbott's (ABT) DAPT for High Bleeding Risk Gets Europe Nod

by Zacks Equity Research

The studies by Abbott (ABT) show that DAPT can be safely discontinued early with no increased risk in patient adverse events.

Here's Why You Should Retain Abbott Laboratories (ABT) Stock

by Zacks Equity Research

Investors remain optimistic about Abbott Laboratories (ABT) owing to strong growth in its molecular and rapid diagnostics business and progress in diabetes arm.

Abbott's (ABT) BinaxNOW Test Gets FDA's EUA for Self Use

by Zacks Equity Research

According to Abbott (ABT), the self-test BinaxNOW together with vaccines will help Americans get back to their regular daily work with greater confidence.

Syneos Health (SYNH) New Partnership to Enhance Clinical Trials

by Zacks Equity Research

Syneos Health (SYNH) new partnership will extend the company's mission to boost research and enable universal patient and provider access with clinical research services.

Here's Why You Should Add Haemonetics (HAE) to Your Portfolio

by Zacks Equity Research

Investor are optimistic about Haemonetics (HAE) on its continued Plasma franchise growth and huge potential of Hemostasis Management franchise.

Abbott (ABT) Nutrition Shows Robust Momentum Amid Pandemic

by Zacks Equity Research

Within Medical Device, Abbott (ABT) Diabetes Care business has been in the limelight for developments in its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

Cardiovascular Systems' (CSII) New Buyout Boosts CAD/PAD Line

by Zacks Equity Research

Cardiovascular Systems' (CSII) acquisition of Peripheral Support Catheters will enhance outcomes for patients undergoing complex peripheral and coronary interventions.

IDEXX (IDXX) CAG Placement Grows Sequentially Amid COVID-19 Woes

by Zacks Equity Research

IDEXX's (IDXX) Global Reference Lab revenues are growing organically in the United States and in international markets.

Insulet's (PODD) Omnipod 5 Pivotal Trial Outcome Favorable

by Zacks Equity Research

Insulet's (PODD) Omnipod 5 pivotal study showed improvement in glucose control, verified by notable reduction in HbA1c and enhanced time in range together with the lowest rates of hypoglycemia.

NuVasive (NUVA) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

NuVasive (NUVA) is optimistic about its strong international performance and a huge growth potential in the spine market.

Penumbra (PEN) Launches INDIGO System Lightning 7 in US

by Zacks Equity Research

Penumbra's (PEN) INDIGO System Lightning 7 assists physicians in easing arterial thrombus removal with single-session results.

    Cardiovascular Systems' (CSII) WIRION Cures 1st U.S Patient

    by Zacks Equity Research

    Cardiovascular Systems' (CSII) WIRION demonstrated a major adverse event rate of 1.9%, which is lower than the earlier reported rates for other lower extremity embolic protection filters.

    Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio

    by Zacks Equity Research

    Investors remain optimistic about Bio-Rad (BIO) backed by strong segmental performance across geographies and robust testing portfolio.

    Abbott's (ABT) Diagnostics Arm to Gain From New & Updated EUAs

    by Zacks Equity Research

    Abbott's (ABT) Alinity m SARS-CoV-2 test set to detect COVID-19 in individuals who do not have symptoms.